Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Launched by HOSPITAL UNIVERSITARIO DR. JOSE E. GONZALEZ · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called blinatumomab for patients with a type of cancer known as B-cell acute lymphoblastic leukemia (B-ALL). Specifically, the trial focuses on patients who have measurable residual disease (MRD), which means that even after treatment, some cancer cells are still present in the body. The goal is to see if a short, 7-day course of blinatumomab can help clear these remaining cancer cells before patients undergo a stem cell transplant, which is a common next step for those with MRD.

To participate in this trial, patients need to have Philadelphia chromosome-negative B-ALL and show detectable MRD while still in complete response to prior treatments. They should also be in reasonably good health, with a performance status score of 0 to 2, meaning they can carry out daily activities with little to no help. Throughout the trial, participants will receive the blinatumomab treatment and will be monitored for any side effects, as well as their overall survival and disease-free survival. It's important to note that some patients may not be eligible if they have certain health issues or have previously received blinatumomab. This trial is currently recruiting participants, so if you or a loved one might be interested, it could be a valuable opportunity to explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
• • MRD detectable in complete response (above the limit of quantification according to FCM)
• • Performance status 0-2 on the ECOG scale
• • No prior organ damage
• • Having a potential related or unrelated donor
• Exclusion Criteria:
• • Performance status on the ECOG scale \>2
• • HCT-CI \>3 points
• • Patients who do not wish to participate in clinical study.
• • Active central nervous system infiltration (CNS3)
• • Active extramedullary disease
• • Having previously received blinatumomab
• • Absence of related or unrelated donors